T3 N1 M0 rectal cancer: optimal initial management is total neoadjuvant therapy

被引：0
|
作者：
Nilsson, Per J. [1 ,2 ]
机构：
[1] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[2] Karolinska Inst, Dept Mol Med & Surg, Euegeniav 6, Hotellet pl 2, SE-17176 Stockholm, Sweden
来源：
BRITISH JOURNAL OF SURGERY | 2024年 / 111卷 / 01期
关键词：
PREOPERATIVE CHEMORADIOTHERAPY; OPEN-LABEL; CHEMOTHERAPY;
D O I：
10.1093/bjs/znad322
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate
    Zagars, GK
    Pollack, A
    Smith, LG
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 44 (04): : 809 - 819
  • [42] The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy
    Zhang, Lu-Ning
    Xiao, Weiwei
    OuYang, Pu-Yun
    You, Kaiyun
    Zeng, Zhi-Fan
    Ding, Pei-Rong
    Pan, Zhi-Zhong
    Xu, Rui-Hua
    Gao, Yuan-Hong
    TUMOR BIOLOGY, 2015, 36 (10) : 8213 - 8219
  • [43] Clinical phase II evaluation of the combination therapy with Docetaxel and Epidoxorubicin in the neoadjuvant, cytostatic treatment on patients with primary breast cancer (T1-4, N0-2, M0)
    Wenzel, C
    Schmidinger, M
    Locker, GJ
    Taucher, S
    Gnant, M
    Jakesz, R
    Steger, GG
    WIENER KLINISCHE WOCHENSCHRIFT, 1999, 111 (20) : 843 - 850
  • [44] Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME)
    X. Serra-Aracil
    C. Pericay
    T. Golda
    L. Mora
    E. Targarona
    S. Delgado
    A. Reina
    F. Vallribera
    J. M. Enriquez-Navascues
    S. Serra-Pla
    J. C. Garcia-Pacheco
    International Journal of Colorectal Disease, 2018, 33 : 241 - 249
  • [45] Management of Clinical T1N0M0 Esophageal Cancer
    Yang, Andrew J.
    Choi, Seo Hee
    Byun, Hwa Kyung
    Kim, Hyun Ju
    Choi, Jinhyun
    Lee, Yong Chan
    Lee, Sang Kil
    Park, Kyung Ran
    Lee, Chang Geol
    GUT AND LIVER, 2019, 13 (03) : 315 - 324
  • [46] NEOADJUVANT CHEMORADIOTHERAPY FOR T3-4N0+RECTAL CARCINOMA
    Dagoglu, N.
    Karaman, S.
    Sakallioglu, B.
    Fayda, M.
    Saglam, S.
    Sakar, B.
    Asoglu, O.
    Balik, E.
    Saglam, E. Kaytan
    Camlyca, H.
    Kizir, A.
    Oral, E. N.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S285 - S285
  • [47] Adjuvant I-131 therapy for T0-3 N1b M0 differentiated thyroid cancer with many (? 5) positive nodes
    Fortune, E. Charles
    Mercado, Catherine E.
    Drew, Peter A.
    Morris, Christopher G.
    Amdur, Robert J.
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2022, 27 (01) : 121 - 124
  • [48] Could radical prostatectomy be a part of prostate cancer treatment T1-3/N1-pN1/M0?
    de la Taille, Alexandre
    PROGRES EN UROLOGIE, 2007, 17 (03): : 23 - 26
  • [49] Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management
    Franke, Aaron J.
    Parekh, Hiral
    Starr, Jason S.
    Tan, Sanda A.
    Iqbal, Atif
    George, Thomas J., Jr.
    CLINICAL COLORECTAL CANCER, 2018, 17 (01) : 1 - 12
  • [50] Modern rectal cancer management: A review of total neoadjuvant therapy and current practices
    Karahan, Salih N.
    Gorgun, Emre
    AMERICAN JOURNAL OF SURGERY, 2025, 241
12345